Abstract
Therapeutic options for severe infections caused by strains of oxacillin-resistant Staphylococcus aureus (ORSA) and coagulase-negative staphylococci (ORSE) are very limited. With the increasing resistance of such strains to aminoglycosides, rifampin, and currently available quinolone agents, as well as the recent documentation of increasing resistance of ORSA to vancomycin (VANCO), new treatment alternatives are imperative. The in vivo efficacy of trovafloxacin (TROVA), a new quinolone agent with excellent antistaphylococcal activity in vitro, against experimental endocarditis (IE) due to beta-lactamase-producing ORSA and ORSE strains (ORSA and ORSE IE) was evaluated. TROVA (25 mg/kg of body weight intravenously [i.v.] twice daily [b.i.d]) was compared to VANCO (20 mg/kg i.v. b.i.d.) and two regimens of ampicillin-sulbactam (AMP-SUL; 200 mg/kg intramuscularly [i.m.] three times a day [t.i.d.] and 20 mg/kg i.m. b.i.d.), with all agents given for 3 or 6 days. AMP-SUL was included as a comparative treatment regimen because of its proven efficacy against experimental ORSA and ORSE IE. For both ORSA and ORSE IE, TROVA, AMP-SUL, and VANCO each reduced staphylococcal densities in vegetations compared to untreated controls (P < 0.01). ...Continue Reading
References
Nov 1, 1991·Annals of Internal Medicine·D P LevineB R Reddy
Apr 1, 1991·Antimicrobial Agents and Chemotherapy·L Hirano, A S Bayer
Jun 1, 1990·Antimicrobial Agents and Chemotherapy·A S Bayer, J Tu
Jul 1, 1990·Chest·A S Bayer, D C Norman
Jun 1, 1990·The Journal of Infectious Diseases·H F Chambers, M Sachdeva
Jan 1, 1989·Chemotherapy·A S BayerC C Nast
Nov 4, 1989·Lancet·R J DworkinH F Chambers
Jul 1, 1989·Antimicrobial Agents and Chemotherapy·C J Hackbarth, H F Chambers
Jan 1, 1989·Antimicrobial Agents and Chemotherapy·E A PiercyP A Mackowiak
Apr 1, 1989·Antimicrobial Agents and Chemotherapy·H F ChambersM Matsuhashi
Aug 1, 1988·The Journal of Infectious Diseases·A S BayerD C Norman
Oct 1, 1988·The Journal of Infectious Diseases·R M MassanariC M Helms
Apr 1, 1988·Journal of Clinical Microbiology·D G SidebottomD A Goldmann
Oct 15, 1988·Annals of Internal Medicine·H F ChambersM D Newman
Dec 1, 1987·Antimicrobial Agents and Chemotherapy·H F Chambers
Oct 1, 1982·Annals of Internal Medicine·O Korzeniowski, M A Sande
Apr 1, 1983·Annals of Internal Medicine·A W KarchmerW E Dismukes
Nov 1, 1994·Antimicrobial Agents and Chemotherapy·H C Neu, N X Chin
Feb 1, 1993·Antimicrobial Agents and Chemotherapy·G M EliopoulosR C Moellering
Jul 1, 1996·The American Journal of Medicine·A W HeldmanC Flexner
Jan 1, 1996·Antimicrobial Agents and Chemotherapy·M C RamosA S Bayer
May 1, 1997·Antimicrobial Agents and Chemotherapy·Y S KimM G Täuber
Jun 1, 1997·The Journal of Antimicrobial Chemotherapy·J VincentH L Friedman
Jul 1, 1997·The Journal of Antimicrobial Chemotherapy·K HiramatsuF C Tenover
Apr 4, 1998·Antimicrobial Agents and Chemotherapy·G W KaatzM J Rybak
Feb 1, 1997·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Alan J. FischmanRobert H. Rubin
Citations
Jan 27, 2006·Antimicrobial Agents and Chemotherapy·John H VernachioJoseph M Patti
Oct 25, 2003·Antimicrobial Agents and Chemotherapy·John VernachioJoseph M Patti
Mar 5, 2008·Antimicrobial Agents and Chemotherapy·Laura LawrenceJoyce Sutcliffe
Jul 29, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R A Proctor
Apr 18, 2002·Antimicrobial Agents and Chemotherapy·Pierre VaudauxDaniel P Lew
Oct 3, 1999·Antimicrobial Agents and Chemotherapy·M BackoA S Bayer